Reneo Pharmaceuticals Statistics Share Statistics Reneo Pharmaceuticals has 3.34M
shares outstanding. The number of shares has increased by -90%
in one year.
Shares Outstanding 3.34M Shares Change (YoY) -90% Shares Change (QoQ) 0% Owned by Institutions (%) 81.62% Shares Floating 3.33M Failed to Deliver (FTD) Shares 1,413 FTD / Avg. Volume 7.86%
Short Selling Information The latest short interest is 5.82M, so 0% of the outstanding
shares have been sold short.
Short Interest 5.82M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 14.23
Valuation Ratios PE Ratio 0 Forward PE -6.72 PS Ratio 0 Forward PS 0.3 PB Ratio 6.04 P/FCF Ratio -12.26 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Reneo Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.73,
with a Debt / Equity ratio of 0.01.
Current Ratio 10.73 Quick Ratio 10.73 Debt / Equity 0.01 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage 181.29
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee n/a Employee Count 8 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 29.08% in the
last 52 weeks. The beta is 0.22, so Reneo Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.22 52-Week Price Change 29.08% 50-Day Moving Average 14.93 200-Day Moving Average 16.04 Relative Strength Index (RSI) 69.89 Average Volume (20 Days) 17,983
Income Statement
Revenue n/a Gross Profit n/a Operating Income -54.39M Net Income n/a EBITDA -54.39M EBIT n/a Earnings Per Share (EPS) 0
Full Income Statement Balance Sheet The company has 110.76M in cash and 1.08M in
debt, giving a net cash position of 109.68M.
Cash & Cash Equivalents 110.76M Total Debt 1.08M Net Cash 109.68M Retained Earnings -154.72M Total Assets 86.07M Working Capital 76.95M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -51.12M
and capital expenditures -52K, giving a free cash flow of -51.17M.
Operating Cash Flow -51.12M Capital Expenditures -52K Free Cash Flow -51.17M FCF Per Share -1.48
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields RPHM does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for RPHM.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside -100% Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Oct 7, 2024. It was a
backward
split with a ratio of 1:10.
Last Split Date Oct 7, 2024 Split Type backward Split Ratio 1:10
Scores Altman Z-Score 2.58 Piotroski F-Score 2
